Roivant posted a net income of $355.7 million or $0.28 per share, compared to consensus estimates of a loss of $0.34, according to Fiscal.ai data. ・The bottom line was lifted by a $770.2 million gain ...
The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of checkpoint inhibitor refractory unresectable or metastatic melanoma with PD-L1+ ...
CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has been dosed in a Phase 1/2 study of mRNA-2808, the Company’s investigational ...